Sarecycline

Paratek is working with Allergan to develop an antibiotic to treat acne: Sarecycline

Paratek is developing sarecycline as a well-tolerated, once-daily, oral, narrow spectrum, tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea.  Allergan owns the U.S. rights for the development and commercialization of sarecycline.  Paratek retains all ex-U.S. rights.  Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.

paratek-pharmaceuticals-sarecycline-acne-skin-treatment

This profile has the potential to provide a best in class acne and rosacea treatment.

Sarecycline has been specifically designed for inflammatory acne and rosacea and has the following characteristics:

  • Narrow spectrum of activity targeting acne and rosacea specific pathogens (P. acnes, staphylococcus aureus)
  • Demonstrated anti-inflammatory activity
  • Limited activity against aerobic gram-negative gastrointestinal organisms compared to minocycline and doxycycline
  • Higher lipophilicity at physiologically relevant pH allowing better penetration into lipid rich sebaceous follicular tissues
  • Long half-life enabling true once-a-day dosing

This profile has the potential to provide a best in class acne and rosacea treatment.

Paratek has retained rest of world (outside of the U.S.) rights to sarecycline and is currently exploring partnership opportunities to develop this antibiotic for acne in appropriate markets.